Skip to Content

News & Events

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain
- VX-409 is first in a new class of subtype selective ion channel modulators -
View HTML
Toggle Summary GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain
- VX-409 is first in a new class of subtype selective ion channel modulators -
View HTML
Toggle Summary FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to
HCV
View HTML
Toggle Summary FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
FDA Grants Fast Track Designation to Vertex’s Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to
View HTML
Toggle Summary Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study
- Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -
View HTML
Toggle Summary Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study
- Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
- Investigational New Drug Application Activated in the U.S. -
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
- Investigational New Drug Application Activated in the U.S. -
View HTML
Toggle Summary FDA Approves Updated Labeling for LEXIVA
- Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -
View HTML
Toggle Summary FDA Approves Updated Labeling for LEXIVA
- Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -
View HTML
Toggle Summary AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor
Vertex Announces Filing of IND in Support of VX-950 Phase II Development in the U.S.
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting
Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting Cambridge, MA, November 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will host a conference call and webcast on Friday, November 11, 2005 at 9:00 a.m. EST.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations
Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Cambridge, MA, October 31, 2005 - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that N. Anthony Coles, M.D., has resigned his position with the Company
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results
- VX-950 Phase Ib Combination Study Initiated -<BR> - Target Enrollment in VX-702 Phase II Rheumatoid Arthritis Study Achieved -
View HTML
Toggle Summary Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis
Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Cambridge, MA, October 4, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will concentrate its development investment in 2006 on
HCV
View HTML
Toggle Summary New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track
New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track Montreal, Canada, October 3, 2005 - New data show that patients with genotype 1 hepatitis C virus (HCV) infection treated with VX-950, an investigational oral HCV
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock
Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock
Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results
Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Cambridge, MA, July 27, 2005 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended June 30, 2005. “Vertex’s progress in the second quarter of 2005 was
View HTML
Toggle Summary Study Results Presented on Pharmacokinetics of Once-Daily HIV Combination Therapy
- Combination of Lexiva/r and Truvada Evaluated -
View HTML
Toggle Summary Long-Term Safety Data of Lexiva/r in HIV Patients Co-Infected with Hepatitis
- Combination of Lexiva/r and Truvada Evaluated -
View HTML
Toggle Summary FDA Grants Fast Track Status for the Investigational HIV Protease Inhibitor 640385 (VX-385)
- GlaxoSmithKline To Initiate Phase IIb Clinical Trial in HIV-infected Patients -
View HTML
Toggle Summary Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680
Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 Whitehouse Station, NJ and Cambridge, MA, June 17, 2005 - Merck &amp; Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of an additional Phase I
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters
Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters Cambridge, MA, June 15, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters have exercised in full their over-allotment option to purchase 1,762,500 shares of common stock
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Completion of Common Stock Offering
Vertex Pharmaceuticals Announces Completion of Common Stock Offering Cambridge, MA, June 13, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offering of 11,750,000 shares of common stock. The gross proceeds, before commissions and expenses, of
View HTML
Toggle Summary Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702
Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702 Cambridge, MA, June 10, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of dosing in a Phase II clinical study in
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentation at Goldman Sachs' Twenty-Sixth Annual Global Healthcare Conference
Vertex Pharmaceuticals Announces Webcast of its Presentation at Goldman Sachs’ Twenty-Sixth Annual Global Healthcare Conference Cambridge, MA, June 9, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at Goldman Sachs' 26th Annual Global Healthcare
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Pricing of Common Stock Offering
Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Cambridge, MA, June 7, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the pricing of its public offering of 11,750,000 shares of its common stock at a price of $13.00 per share.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock
Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA, May 31, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to offer 9,500,000 shares of its newly issued common stock in an underwritten public offering.
View HTML
Toggle Summary Vertex Pharmaceuticals Reports that Oral Hepatitis C Protease Inhibitor, VX-950, Dramatically Reduces Viral Levels in Phase Ib Clinical Study
-- Five Patients on 14-day Clinical Study Achieve Plasma Levels Below Limit of Quantitation --
HCV
View HTML
Toggle Summary Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
-- Eugene Cordes, Ph.D., Appointed to Vertex's Board of Directors --
View HTML
Toggle Summary Vertex Pharmaceuticals Reports that VX-950, an Investigational Oral Hepatitis C Protease Inhibitor, Displays Potent Antiviral Activity in Early Clinical Study
- Presentation of Study Results Planned at DDW -
HCV
View HTML
Toggle Summary Vertex Pharmaceuticals to Webcast its 2005 Annual Meeting of Shareholders
Vertex Pharmaceuticals to Webcast its 2005 Annual Meeting of Shareholders Cambridge, MA, May 5, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will webcast its 2005 Annual Meeting of Shareholders on Wednesday, May 11, 2005. Joshua Boger, Ph.D., Vertex's Chairman and Chief Executive
View HTML
Toggle Summary New Pharmacokinetic Data On Taking Lexiva Simultaneously With Nexium
New Pharmacokinetic Data On Taking Lexiva Simultaneously With Nexium Quebec City, April 29, 2005 --Today GlaxoSmithKline (GSK) presented new pharmacokinetic (PK) data on taking the HIV protease inhibitor LEXIVA(R) (fosamprenavir calcium, FPV) Tablets with the proton pump inhibitor (PPI), Nexium(R)
View HTML
Toggle Summary New Pharmacokinetic Data on Co-Administration of the PI LEXIVA/r With the NRTI Tenofovir
New Pharmacokinetic Data on Co-Administration of the PI LEXIVA/r With the NRTI Tenofovir Quebec City, April 29, 2005 --Today new study results announced by GlaxoSmithKline showed the pharmacokinetics (PK) of the HIV protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed in combination with
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences
Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences Cambridge, MA, April 27, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at Deutsche Bank's 30th Annual Health Care Conference on May 2, 2005 and at Morgan Stanley's
View HTML
Toggle Summary Vertex Pharmaceuticals Reports First Quarter 2005 Financial Results and Provides Clinical Update
Vertex Pharmaceuticals Reports First Quarter 2005 Financial Results and Provides Clinical Update Cambridge, MA, April 26, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended March 31, 2005.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces the Date of its First Quarter 2005 Financial Results Conference Call and Webcast
Vertex Pharmaceuticals Announces the Date of its First Quarter 2005 Financial Results Conference Call and Webcast Cambridge, MA, April 4, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will announce its first quarter 2005 financial results on Tuesday, April 26, 2005 after the financial
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentation at the 25th Annual SG Cowen Health Care Conference
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 25th Annual SG Cowen Health Care Conference Cambridge, MA, March 11, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at SG Cowen's 25th Annual Health Care Conference in Boston.
View HTML
Toggle Summary Federal Court Orders Dismissal of Shareholder Lawsuit Against Vertex Pharmaceuticals
Federal Court Orders Dismissal of Shareholder Lawsuit Against Vertex Pharmaceuticals Cambridge, MA, February 23, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the United States District Court for the District of Massachusetts has granted its motion to dismiss a
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences
Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences Cambridge, MA, February 18, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the BIO CEO and Investor Conference on February 23, 2005 and at the SunTrust Robinson
View HTML
Toggle Summary Vertex Pharmaceuticals Licenses VX-944 to Avalon Pharmaceuticals for Development and Commercialization in the Treatment of Cancer
Vertex Pharmaceuticals Licenses VX-944 to Avalon Pharmaceuticals for Development and Commercialization in the Treatment of Cancer Cambridge, MA, and Germantown, MD, February 15, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Avalon Pharmaceuticals Incorporated today announced that
View HTML
Toggle Summary Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance
Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance Cambridge, MA, February 9, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter and year ending December 31, 2004.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Two Senior Management Changes
Vertex Pharmaceuticals Announces Two Senior Management Changes Cambridge, MA, February 8, 2005 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that Dr. Vicki Sato will retire as President of the Company effective during the second quarter of 2005. Dr.
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2005 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2005 Merrill Lynch Global Pharmaceutical, Biotechnology &amp; Medical Device Conference Cambridge, MA, February 3, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at Merrill Lynch's
View HTML
Toggle Summary Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2004 Financial Results Conference Call and Webcast
Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2004 Financial Results Conference Call and Webcast Cambridge, MA, February 2, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will announce its fourth quarter and full year 2004 financial results on Wednesday,
View HTML
Toggle Summary Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference
Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 10, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today will review its 2004 achievements and will describe its 2005
View HTML
Toggle Summary Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers
Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers Whitehouse Station, NJ and Cambridge, MA, January 6, 2005 -- Merck &amp; Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have begun a Phase I
View HTML
Toggle Summary Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 5, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at JPMorgan's 23rd Annual Healthcare Conference in San
View HTML
Toggle Summary Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART
Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART Montego Bay, Jamaica, December 15, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) plus ritonavir (LEXIVA/r) dosed once daily (QD)
View HTML